FARXIGA, XIGDUO XR, GLYXAMBI, AND JARDIANCE LAWSUITS
Farxiga, Xigduo XR, Glyxambi, and Jardiance Lawsuits
Adults with Type 2 diabetes rely on prescription drugs like Farxiga (or its extended release counterpart, Xigduo XR), Glyxambi, and Jardiance to help lower their blood sugar, but some are reporting that they’ve suffered serious injuries after taking the medications. Our attorneys at Morgan & Morgan are investigating claims that these drugs could cause serious kidney problems, diabetic coma, and even death, in some patients.
If Farxiga, Xigduo XR, Glyxambi, or Jardiance injured you or a loved one, contact us today for a free case evaluation. It’s of no risk to you: You don’t pay a thing unless we win your case.
About Farxiga, Xigduo XR, Glyxambi, or Jardiance
The drugs are all similar — they are each classified as a sodium-glucose cotransporter 2 inhibitor (or SGLT2 inhibitor), which is a type of drug used to help lower blood sugar in patients suffering from Type 2 diabetes. Specific information about each of them is below.
Farxiga (dapagliflozin) is manufactured by Bristol-Myers Squibb and AstraZeneca, and was approved by the U.S. Food and Drug Administration in 2014. That same year, the FDA approved Xigduo XR, a combination of dapagliflozin and metformin hydrochloride that is an extended-release version of Farxiga.
Glyxambi is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co. It combines two commonly prescribed diabetes drugs, empagliflozin (Jardiance) and linagliptin (Tradjenta). In 2015, the FDA approved Glyxambi, and at the time of its launch it was heralded as a better way to lower blood-sugar levels than either of the two contributing drugs on their own.
As a solo drug Jardiance, the Boehringer medication, earned FDA approval in July 2014. Although the drug’s initially approved treatment was lowering blood pressure in Type 2 diabetes suffers, in 2016 the FDA approved Jardiance for a new indication — for treating patients with both Type 2 diabetes and cardiovascular issues.
Dangerous Side Effects
The problem with these SGLT2 inhibitors is that they are known to cause a host of side effects, including hypoglycemia, urinary tract infections, and yeast infections. However, there are also some serious and potentially life-changing side effects that people should be aware of, according to a 2016 FDA drug safety announcement.
Here is a short but important list of the dangerous side effects attributed to these diabetes drugs:
- Acute kidney injury and impairment in renal function;
- Ketoacidosis (also known as acidosis or diabetic ketoacidosis) — a condition that causes the body to produce excessive levels of blood acids, or ketones, leading to the fatal symptoms;
Why People Are Filing Farxiga, Xigduo XR, Glyxambi, or Jardiance Lawsuits
Farxiga and the other SGLT2 inhibitors, Jardiance, Xigduo XR, and Glyxambi, might put patients at severe risk of potentially fatal injuries, when all those patients want to do is treat the condition they have to live with every day.
Diabetes patients who took these drugs and suffered injuries may be entitled to compensation for medical bills, lost wages, pain and suffering, and, in the case of death, funeral costs.
Do You Qualify for a Farxiga, Xigduo XR, Glyxambi, or Jardiance Lawsuit?
To be eligible for a lawsuit, you or your loved one would have to have taken Farxiga, Xigduo XR, Jardiance, or Glyxambi, and suffered ketoacidosis, kidney injury, or another type of unforeseen injury. The death of a patient taking one of those drugs could also be a cause to file a lawsuit.
Were you harmed? You shouldn’t have to go through this alone — you trust that the medications you take will heal you, not harm you. Let our class action and mass torts attorneys help you today. Contact us for a free, no-risk case evaluation.